This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
While the company reported strong third-quarter results, United Therapeutics suffered a major blow in October with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for its new drug application for oral Remodulin (treprostinil). The company was looking to get oral Remodulin approved for the treatment of pulmonary arterial hypertension (PAH).
Although United Therapeutics said that it intends to gain approval for the candidate within four years, we have low visibility on the company’s development plans for the candidate.
The company's lead product is Remodulin, an injectable formulation of treprostinil, indicated for the treatment of PAH in patients with New York Heart Association (NYHA) Class II-IV symptoms. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. The other two PAH products in the company’s portfolio are Adcirca (tadalafil) and Tyvaso.
United Therapeutics holds a strong position in the PAH market with three approved products targeting this indication. Lead product Remodulin continues to look very strong in both the IV and SC forms. EU approval for the IV formulation, received in late December 2011, should drive sales further. The company is looking to launch Remodulin in new territories including Japan and China. The Japanese market could bring in incremental sales of about $100 million.
Although we believe United Therapeutics' existing PAH product portfolio will drive strong top-and bottom-line growth, we remain concerned about the company’s dependence on Remodulin for revenues.
Remodulin, which accounted for 57.9% of total sales in 2011, is currently facing a generic challenge from Sandoz, Novartis’ (NVS - Snapshot Report) generic division. The company needs to develop products that could help make up for the loss of revenues in the event of genericization of Remodulin.
Please login to Zacks.com or register to post a comment.